Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 16.89B +126.2% |
| Revenue (ttm) | 4.60B +12.6% |
| Net Income | 940.75M |
| EPS | 14.63 |
| Shares Out | 64.91M |
| PE Ratio | 17.78 |
| Forward PE | 10.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,560,216 |
| Open | 256.36 |
| Previous Close | 254.47 |
| Day's Range | 254.59 - 266.38 |
| 52-Week Range | 122.50 - 266.38 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 285.80 (+9.83%) |
| Earnings Date | Aug 3, 2026 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price target is $285.8, which is an increase of 9.83% from the latest price.
News
Jazz Pharmaceuticals price target raised to $300 from $287 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $300 from $287 and keeps a Buy rating on the shares. The firm cites the…
Jazz Pharmaceuticals Transcript: FDA announcement
FDA approved Ziihera as the first bispecific HER2-targeted antibody with a PD-1 inhibitor and chemotherapy for first-line HER2-positive metastatic GEA, showing unprecedented survival benefits. The launch leverages established infrastructure, with peak sales projected at $3B-$5B and ongoing expansion into additional tumor types.
Jazz Pharmaceuticals Press release: FDA announcement
Jazz Pharmaceuticals issued a press release on August 25, 2026, disclosing material business information to investors.
Jazz Pharmaceuticals Slides: FDA announcement
Jazz Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Jazz Pharmaceuticals announces FDA approval of two Ziihera-containing regimens
Jazz Pharmaceuticals (JAZZ) announced that the U.S. FDA approved two Ziihera-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive g...
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front...
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million. Deal centers around Actio's lead drug for KCNT+ epilepsy, ABS-1230.
Jazz Pharmaceuticals price target raised to $283 from $280 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $283 from $280 and keeps an Overweight rating on the shares after the company announced it will acquire…
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at up to $1.32 billion, adding an experimental treatment for a rare inherited form of epilepsy that...
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront
07:30 EDT Jazz Pharmaceuticals (JAZZ) to acquire Actio Biosciences for $820M upfront
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront
Jazz Pharmaceuticals (JAZZ) and Actio Biosciences announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820M upfront and up to $500...
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction i...
Jazz Pharmaceuticals price target raised to $300 from $290 at Canaccord
Canaccord analyst Gary Nachman raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $300 from $290 and keeps a Buy rating on the shares. The firm said 2Q highighted…
Jazz Pharmaceuticals price target raised to $287 from $270 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $287 from $270 and keeps a Buy rating on the shares.
Jazz Pharmaceuticals price target raised to $280 from $245 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $280 from $245 and keeps an Overweight rating on the shares.
Jazz Pharmaceuticals price target raised to $300 from $275 at TD Cowen
TD Cowen raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $300 from $275 and keeps a Buy rating on the shares. The firm updated its model as the…
Jazz Pharmaceuticals price target raised to $264 from $254 at Truist
Truist raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $264 from $254 and keeps a Buy rating on the shares. Jazz delivered a topline beat with stronger sleep…
Jazz Pharmaceuticals price target raised to $300 from $285 at Wells Fargo
Wells Fargo raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $300 from $285 and keeps an Overweight rating on the shares. The firm says the beat and raise…
Jazz Pharmaceuticals price target raised to $315 from $307 at UBS
UBS raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $315 from $307 and keeps a Buy rating on the shares. The strong Q2 performance reinforces confidence in the…
Jazz Pharmaceuticals price target raised to $275 from $230 at Stifel
Stifel raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $275 from $230 and keeps a Buy rating on the shares. A “meaningfully diversified portfolio” delivered revenues above consensus…
Jazz Pharmaceuticals price target raised to $276 from $265 at JPMorgan
JPMorgan raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $276 from $265 and keeps an Overweight rating on the shares. The firm views the company’s Q2 report as…
Jazz Pharmaceuticals price target raised to $310 from $301 at Piper Sandler
Piper Sandler raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $310 from $301 and keeps an Overweight rating on the shares following quarterly results. The firm continues to…
Jazz Pharmaceuticals price target raised to $280 from $252 at Baird
Baird raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $280 from $252 and keeps an Outperform rating on the shares. The firm updated its model as Xyway and…
Jazz Pharmaceuticals price target raised to $270 from $260 at Barclays
Barclays raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $270 from $260 and keeps an Overweight rating on the shares following the Q2 report. The company reported 16%…
Jazz Pharmaceuticals Earnings Call Transcript: Q2 2026
Record Q2 revenue of $1.21B (up 16% YoY) driven by strong growth in oncology, sleep, and epilepsy portfolios. Raised 2026 revenue guidance to $4.60–$4.75B, with robust launches, pipeline progress, and limited generic impact supporting momentum.